




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Asymptomatic Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: Extent and implications for infection control: A systematic review

Jaffar A. Al-Tawfiq^{a,b,c,*}, Philippe Gautret^d

^a Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia

^b Indiana University School of Medicine, Indianapolis, IN, USA

^c Johns Hopkins University School of Medicine, Baltimore, MD, USA

^d Aix Marseille Univ, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), Service de Santé des Armées (SSA), Microbes Vecteurs Infections Tropicales et Méditerranéennes (VITROME), Institut Hospitalo-Universitaire-Méditerranée Infection (IHU-Méditerranée Infection), Marseille, France

ARTICLE INFO

Keywords:

Middle East Respiratory Syndrome Coronavirus
MERS
Healthcare associated outbreaks

ABSTRACT

Background: The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) emerged in 2012 and attracted an international attention as the virus caused multiple healthcare associated outbreaks. There are reports of the role of asymptomatic individuals in the transmission of MERS-CoV, however, the exact role is not known.

Method: The MEDLINE/PubMed and Scopus databases were searched for relevant papers published till August 2018 describing asymptomatic MERS-CoV infection.

Results: A total of 10 papers were retrieved and included in the final analysis and review. The extent of asymptomatic MERS infection had increased with change in the policy of testing asymptomatic contacts. In early cases in April 2012–October 2013, 12.5% were asymptomatic among 144 PCR laboratory-confirmed MERS-CoV cases while in 2014 the proportion rose to 25.1% among 255 confirmed cases. The proportion of asymptomatic cases reported among pediatric confirmed MERS-CoV cases were higher (41.9%–81.8%). Overall, the detection rate of MERS infection among asymptomatic contacts was 1–3.9% in studies included in this review. Asymptomatic individuals were less likely to have underlying condition compared to fatal cases. Of particular interest is that most of the identified pediatric cases were asymptomatic with no clear explanation.

Conclusions: The proportion of asymptomatic MERS cases were detected with increasing frequency as the disease progressed overtime. Those patients were less likely to have comorbid disease and may contribute to the transmission of the virus.

1. Introduction

The emergence of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012 had attracted an international attention as the virus had cause multiple healthcare associated outbreaks [1–21] within the Kingdom of Saudi Arabia [1,2,6,8,9,13] and outside Saudi Arabia [4,5,22,23]. As of December 7, 2018, the World Health Organization reported 2267 laboratory-confirmed cases worldwide and at least 804 related deaths in 27 countries [24]. Despite the increase in the number of cases, the actual incidence of MERS-CoV among hospitalized patients with community acquired pneumonia is low. In a longitudinal study from 2012 to 2016, a total of 2657 patients were screened for MERS-CoV and only 20 (0.74%) tested positive [25]. The study showed that MERS-CoV was rare in admitted patients with community acquired pneumonia and influenza was more common than

MERS [25]. The explanation for the increased number of cases is the occurrence of multiple outbreaks as the hallmark of MERS-CoV transmission [26]. The main patterns of MERS-CoV transmissions are: sporadic community cases from presumed non-human exposure, family clusters resulting from contact with an infected family index case, and healthcare-acquired infections between patients and from patients to healthcare workers [5]. In addition, there were multiple occasions of transmission within the same family and that travel associated transmission of MERS-CoV poses a concern [27,28].

There are reports of the role of asymptomatic individuals in the transmission of MERS-CoV, however, the exact role is not known [26]. Many viral infections are associated with asymptomatic, subclinical, or very mild symptoms. In the case of poliomyelitis, 95% of those infected remain asymptomatic, yet they are still capable of spreading the virus (CDC). In one study, asymptomatic rhinovirus infection was four times

* Corresponding author. P.O. Box 76, Room A-428-2, Building 61, Dhahran Health Center, Saudi Aramco, Dhahran, 31311, Saudi Arabia.

E-mail addresses: jaffar.tawfiq@jhah.com, jaltawfi@yahoo.com (J.A. Al-Tawfiq).

<https://doi.org/10.1016/j.tmaid.2018.12.003>

Received 2 October 2018; Received in revised form 7 December 2018; Accepted 10 December 2018

Available online 11 December 2018

1477-8939/ © 2018 Elsevier Ltd. All rights reserved.




Fig. 1. A flow diagram of the search strategy according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [32].

as common as symptomatic infection [29]. Another study found asymptomatic carriage of influenza virus to be 5.2–35.5% [30]. During the severe acute respiratory syndrome (SARS) outbreak, a study examined the rate of positive healthcare workers (HCWs) who were exposed to patients with SARS before infection control measures were applied [31]. Asymptomatic SARS based on serology was 13% compared to severe disease in 82% and 4% of mild symptoms [31]. In this article, we systematically review the available literature on the occurrence of asymptomatic MERS-CoV infection and shed light on the possible role of those in the transmission of the virus.

1.1. Search strategy

We searched MEDLINE and Scopus databases for articles in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (<http://www.prismastatement.org>) [32]. We included the following terms:

- #1: “Middle East Respiratory Syndrome Coronavirus” OR “MERS” OR “MERS-CoV” OR “Novel Coronavirus”
- #2: “Asymptomatic”
- #3: “transmission”
- #4: #1 AND #2 AND #3.

Early in the course of the MERS outbreak, the term MERS was not yet coined and the term Novel Coronavirus was used. Thus, we also conducted a focused search to identify any missed relevant publications.

We included articles describing transmission of MERS-CoV in animals and humans from asymptomatic infection.

2. Results

Initial screening of retrieved articles excluded articles which were:

review articles, and those which did not include specific rates or cases of asymptomatic MERS-CoV infection. A total of 10 papers were retrieved and included in the final analysis and review (Fig. 1, Table 1) [6,33–41]. We included studies in humans describing the incidence of asymptomatic MERS [6,33–40] and two additional studies in animals [42,43].

2.1. Animal infection

In a rabbit model of MERS-CoV infection, MERS-CoV was detected in the lungs without significant histopathological changes and no symptoms [42]. In an evaluation of contacts of a positive dromedary camel, 2 (5.8%) of 34 dromedary contacts tested positive and were asymptomatic [43].

2.2. Extent of asymptomatic MERS in humans

The proportion of asymptomatic MERS probably remained unchanged, or even declined with implementation of personal protection measures; asymptomatic case identification increased by change in testing recommendations. This change had also resulted in the reduction of case-fatality rate from 65% mainly in severe cases to 44.5% in mixed population [44]. This reduction was partially related to an increase in the rate of asymptomatic individuals from 0% to 28.6% in early reports [44]. A summary of studies addressing asymptomatic MERS cases in Humans is shown in Table 1. In early cases from April 2012 to October 2013, there were 144 laboratory-confirmed MERS-CoV cases including 18 (12.5%) asymptomatic individuals [33]. In one study from Saudi Arabia, 4 (0.8%) of 520 asymptomatic HCWs screened were positive [35]. In South Korea, 3 (0.5%) of 591 asymptomatic HCWs were detected positive via PCR screening [34]. In a recent study from Saudi Arabia, 17 out of 879 HCWs tested positive for MERS-CoV and 53% of them were asymptomatic by PCR [41].

In a seroepidemiologic survey conducted in South Korea, of 1610

Table 1
A summary of studies addressing asymptomatic MERS cases in Humans.

| Study | Year | Setting | Method of diagnosis | Total number of confirmed MERS cases | Proportion of asymptomatic cases among confirmed cases (%) | Number of confirmed cases among asymptomatic screened contacts | Reference |
|-------|--|--|---------------------------|--------------------------------------|--|--|-----------|
| 1 | April 2012 to October 2013 | Laboratory-confirmed and probable MERS-CoV symptomatic cases from 9 countries | PCR | 144 | 18 (12.5%) | - | [33] |
| 2 | December 2012 and August 2013 | Asymptomatic Saudi Arabian HCWs contacts (n = 520 screened) | PCR | 4 | - | 4/520 (0.8%) | [35] |
| 3 | 2015 | Asymptomatic South Korea HCWs contacts (n = 591 screened) | PCR | 3 | - | 3/591 (0.5%) | [34] |
| 4 | 2015 | South Korea HCWs (n = 574 screened) and non-HCWs contacts (n = 307 screened) | Serology (ELISA/IFA/PRNT) | 1 | - | 0/574 HCWs 1/307 non-HCWs (0.3%) | [36] |
| 5 | January 1 through May 16, 2014 | Laboratory-confirmed cases reported to the Saudi Arabian Ministry of Health during the Jeddah Outbreak | PCR | 255 | 64 (25.1%) including 41 HCWs and 23 non-HCWs | - | [6] |
| 6 | June 4, 2013, to November 5, 2013 | Saudi Arabian household contacts (N = 280 screened) | PCR or serology | 12 | 11 (91.7%) | Not available | [37] |
| 7 | September 1, 2012, to December 2, 2013 | Laboratory-confirmed pediatric cases reported to the Saudi Arabian Ministry of Health | PCR | 11 | 9 (81.8%) | - | [38] |
| 8 | June 2012, to April 19, 2016 | Laboratory-confirmed pediatric cases reported to the Saudi Arabian Ministry of Health | PCR | 31 | 13 (41.9%) | - | [39] |
| 9 | April 2014 to November 2016 | Laboratory-confirmed pediatric cases admitted to one Saudi Arabian Hospital | PCR | 7 | 3 (42.8%) | - | [40] |
| 10 | June 2017 Outbreak | Healthcare workers contacts at one hospital in Saudi Arabia | PCR | 879 | 15 (53%) | - | [41] |

asymptomatic HCWs and non-HCWs contacts only 1 non-HCW (0.06%) tested positive [36]. Asymptomatic persons were identified in the Jeddah outbreak. There were 64 (25%) asymptomatic of 255 individual tested including 41 HCWs and 23 non-HCWs [6]. In a total of 280 household contacts, 12 individuals were identified by PCR or serology of whom 11 (3.9%) were asymptomatic [37]. Asymptomatic individuals were less likely to have underlying condition (42%) compared to 86% of fatal cases [45]. However, serologic evaluation of contacts and patients may underestimate the extent of the disease as antibodies wane over time and is related to disease severity [46]. Of particular interest is that most of the identified pediatric cases were asymptomatic with no clear explanation [38–40,47].

Overall, the detection rate of MERS cases among asymptomatic contacts when screened was less than 1% in the available studies included in this review (Table 1). The proportion of asymptomatic cases among all confirmed cases, widely differed in the available reports. The differences between the study setting and the populations studied did not allow any reliable comparison. According to the last WHO update 21% of the 2228 cases confirmed MERS-CoV cases were reported to have no or mild symptoms while 46% had severe disease or died [48].

2.3. Asymptomatic travelers

Imported MERS-CoV cases were treated in healthcare settings. More than 20 travel-related MERS-CoV had occurred as summarized previously [28]. However, there were no reported asymptomatic cases. Travel related MERS-CoV occurred infrequently among pilgrims performing Umrah [28,49].

3. Discussion

3.1. Role of asymptomatic individuals in MERS-CoV infection

The role of asymptomatic individuals was evaluated in a family cluster [50]. The index case in that study was thought to have acquired MERS infection from an unrecognized mild or asymptomatic case [50]. However, the link was not established in this case. One study suggested the possible transmission of MERS from an asymptomatic individual. The index case of a family cluster acquired infection 14 days after hospitalization suggesting that the infection occurred from an asymptomatic person [50]. This is based on an incubation period of 7–10 days. In the South Korea outbreak, 82 contacts of an asymptomatic or mild MERS-CoV infection were tested by RT-PCR and serology and all of them were negative [51]. In a study from Abu Dhabi, of 34 case-patients, 91% were asymptomatic with no evidence of transmission [52]. In another study, most of the cases were either asymptomatic or mildly symptomatic [53]. MERS-CoV was cultured from a patient with mild respiratory symptoms confirming the ability of such patients to transmit MERS-CoV [54].

The role of asymptomatic travelers in the potential transmission of the infection to household contacts is a concern. However, so far no such event had been reported. The risk of MERS-CoV infection seems to be low in travelers [49], and there were multiple cases described in travelers [28]. The risk of MERS-CoV was evaluated in a mathematical study and the model included all Middle East countries with reported locally acquired cases, and 41% of the travel-imported cases outside the Middle East were in the top ten countries [55]. Although, India was the most at-risk country, there had been no reported cases from this country.

The initial 2012 Hajj season started few weeks after the first case of MERS-CoV infection was reported [56]. However, there were no reported cases among pilgrims in 2012 [57–60]. Thus, the Saudi Ministry of Health utilized the MERS-CoV case definition for monitoring any occurrence of the disease during Hajj for early detection of cases among pilgrims [61]. An enhanced surveillance system was established for the detection of MERS-CoV cases. The disease remains limited to the Middle

East with the exception of sporadic travel associated infections and the large outbreak in South Korea [22,28,62,63]. In one study conducted September 2012–October 2013, 77 travelers from the Middle East met the possible case definition for MERS and two of them tested positive for MERS [28]. In a small study of 14 returning Pilgrims, all patients were hospitalized for respiratory symptoms and none of them tested positive for MERS-CoV in Marseille France in October 2013 [64]. Furthermore, nasopharyngeal swabs were collected from suspected cases and all samples tested negative for MERS-COV [56]. Another small study of 7 Pilgrims in 2014 in Austria, none had MERS-CoV [65].

Mathematical models estimated the risk of MERS-CoV among pilgrims to be 1–7 cases per Hajj, and 3–10 per Umrah per year [66]. It was estimated that 6.2 pilgrims may develop MERS-CoV symptoms during the Hajj, and 4 pilgrims may become infected and return home before symptoms development [67]. However, systematic screening of pilgrims for MERS-CoV showed no positive cases [59,65,68–81]. Systematic surveillance of returning Pilgrims was done in several studies in Egypt, Iran, France, Ghana, Iran and Saudi Arabia [64,68,71,72]. Few studies examined MERS-CoV among symptomatic pilgrims and none was positive for MERS-CoV [56,59,65,81]. There had been an extensive surveillance of MERS-CoV among pilgrims and only 4 cases have been linked to Umrah (Mini-Hajj) [82–86].

3.2. Infection control implications

The occurrence of asymptomatic infection of MERS and the possibility of transmission to other individuals is of particular importance for healthcare settings and for travelers. These RT-PCR positive persons with mild or no symptoms are usually identified when conducting laboratory screening tests as part of active case monitoring or contact investigations. Asymptomatic health care workers may contribute to healthcare associated transmission and asymptomatic travelers may potentially transmit the infection to household contacts. The WHO recommends the isolation of asymptomatic PCR-positive individuals and daily follow up for the occurrence of symptoms. Those individuals should be tested at least weekly and HCWs should not return to work until two consecutive upper respiratory tract samples are RT-PCR negative [87]. In a study of severe cases and those with mild disease, the latter group cleared MERS-CoV at an earlier time than patients with severe disease whereby on day 12, 30% of mild cases and 76% of severe cases were positive for MERS-CoV by PCR [88]. Another study reported prolonged nasal virus RNA detection (more than 5 weeks) from one asymptomatic RT-PCR positive health-care worker [89].

In conclusion, the proportion of asymptomatic MERS cases were detected with increasing frequency as the disease progressed overtime. Those patients were less likely to have comorbid disease and may contribute to the transmission of the virus.

Financial support

All authors have no funding.

Conflicts of interest

All authors have no conflict of interest to declare.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.tmaid.2018.12.003>.

References

- [1] Drosten C, Muth D, Corman VM, Hussain R, Al Masri M, HajOmar W, et al. An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014. *Clin Infect Dis* 2015;60:369–77. <https://doi.org/10.1093/cid/ciu812>.
- [2] Assiri A, McGeer A, Perl TM, Price CS, Al Rabeah AA, Cummings DAT, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. *N Engl J Med* 2013;369:407–16. <https://doi.org/10.1056/NEJMoa1306742>.
- [3] Al-Abdallat MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. *Clin Infect Dis* 2014;59:1225–33. <https://doi.org/10.1093/cid/ciu359>.
- [4] Hijawi B, Abdallat M, Sayaydeh A, Alqasrawi S, Haddadin A, Jaarour N, et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. *East Mediterr Health J* 2013;19(Suppl 1):S12–8.
- [5] Al-Tawfiq JA, Memish ZA. Drivers of MERS-CoV transmission: what do we know? *Expert Rev Respir Med* 2016;10:331–8. <https://doi.org/10.1586/17476348.2016.1150784>.
- [6] Oboho IK, Tomczyk SM, Al-Asmari AM, Banjar AA, Al-Mugti H, Aloraini MS, et al. 2014 MERS-CoV outbreak in Jeddah—a link to health care facilities. *N Engl J Med* 2015;372:846–54. <https://doi.org/10.1056/NEJMoa1408636>.
- [7] Alraddadi B, Bawareth N, Omar H, Alsalmi H, Alshukairi A, Qushmaq I, et al. Patient characteristics infected with Middle East respiratory syndrome coronavirus infection in a tertiary hospital. *Ann Thorac Med* 2016;11:128–31. <https://doi.org/10.4103/1817-1737.180027>.
- [8] Fagbo SF, Skakni L, Chu DKW, Garbati MA, Joseph M, Peiris M, et al. Molecular epidemiology of hospital outbreak of Middle East respiratory syndrome, Riyadh, Saudi Arabia, 2014. *Emerg Infect Dis* 2015;21:1981–8. <https://doi.org/10.3201/eid2111.150944>.
- [9] Almekhlafi GA, Albarrak MM, Mandourah Y, Hassan S, Alwan A, Abudayah A, et al. Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients. *Crit Care* 2016;20:123. <https://doi.org/10.1186/s13054-016-1303-8>.
- [10] Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. *Int J Infect Dis* 2014;29:301–6. <https://doi.org/10.1016/j.ijid.2014.09.003>.
- [11] Memish ZA, Al-Tawfiq JA, Alhakeem RF, Assiri A, Alharby KD, Almahallawi MS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): a cluster analysis with implications for global management of suspected cases. *Trav Med Infect Dis* 2015;13:311–4. <https://doi.org/10.1016/j.tmaid.2015.06.012>.
- [12] El Bushra HE, Abdalla MN, Al Arbash H, Alshayeb Z, Al-Ali S, Latif ZA-A, et al. An outbreak of Middle East respiratory syndrome (MERS) due to coronavirus in Al-Ahsa Region, Saudi Arabia, 2015. *East Mediterr Health J* 2016;22:468–75.
- [13] Balkhy HH, Alenazi TH, Alshamrani MM, Baffoe-Bonnie H, Al-Abdely HM, El-Saed A, et al. Notes from the field: nosocomial outbreak of Middle East respiratory syndrome in a large tertiary care hospital—Riyadh, Saudi Arabia, 2015. *MMWR Morb Mortal Wkly Rep* 2016;65:163–4. <https://doi.org/10.15585/mmwr.mm6506a5>.
- [14] Balkhy HH, Alenazi TH, Alshamrani MM, Baffoe-Bonnie H, Arabi Y, Hijazi R, et al. Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia. *Infect Control Hosp Epidemiol* 2016;37:1147–55. <https://doi.org/10.1017/ice.2016.132>.
- [15] Assiri AM, Biggs HM, Abedi GR, Lu X, Bin Saeed A, Abdalla O, et al. Increase in Middle East respiratory syndrome-coronavirus cases in Saudi Arabia linked to hospital outbreak with continued circulation of recombinant virus, July 1–August 31, 2015. *Open Forum Infect Dis* 2016;3. <https://doi.org/10.1093/ofid/ofw165>.
- [16] Nazer RI. Outbreak of Middle East respiratory syndrome-coronavirus causes high fatality after cardiac operations. *Ann Thorac Surg* 2017;104:e127–9. <https://doi.org/10.1016/j.athoracsur.2017.02.072>.
- [17] Assiri A, Abedi GR, Bin Saeed AA, Abdalla MA, al-Masry M, Choudhry AJ, et al. Multifacility outbreak of Middle East respiratory syndrome in Taif, Saudi Arabia. *Emerg Infect Dis* 2016;22:32–40. <https://doi.org/10.3201/eid2201.151370>.
- [18] Hunter JC, Nguyen D, Aden B, Al Bandar Z, Al Dhaheri W, Abu Elkheir K, et al. Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi. *Emerg Infect Dis* 2016;22:647–56. <https://doi.org/10.3201/eid2204.151615>.
- [19] Cauchemez S, Van Kerkhove MD, Riley S, Donnelly CA, Fraser C, Ferguson NM. Transmission scenarios for middle east respiratory syndrome coronavirus (MERS-CoV) and how to tell them apart. *Euro Surveill* 2013;18. pii: 20503.
- [20] Cauchemez S, Fraser C, Van Kerkhove MD, Donnelly CA, Riley S, Rambaut A, et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. *Lancet Infect Dis* 2014;14:50–6. [https://doi.org/10.1016/S1473-3099\(13\)70304-9](https://doi.org/10.1016/S1473-3099(13)70304-9).
- [21] Chowell G, Abdirizak F, Lee S, Lee J, Jung E, Nishiura H, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. *BMC Med* 2015;13:210. <https://doi.org/10.1186/s12916-015-0450-0>.
- [22] Kim Y, Lee S, Chu C, Choe S, Hong S, Shin Y. The characteristics of middle eastern respiratory syndrome coronavirus transmission dynamics in South Korea. *Osong Public Heal Res Perspect* 2016;7:49–55. <https://doi.org/10.1016/j.phrp.2016.01.001>.
- [23] Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiologic assessment of MERS-CoV outbreak in South Korea, May–June 2015. *Euro Surveill* 2015;20.
- [24] World Health Organization (WHO). Middle East respiratory syndrome coronavirus (MERS-CoV). WHO; 2017 <http://www.who.int/emergencies/mers-cov/en/>, Accessed date: 30 April 2017.
- [25] Al-Tawfiq JA, Rabaan AA, Hinedi K. Influenza is more common than Middle East Respiratory Syndrome Coronavirus (MERS-CoV) among hospitalized adult Saudi

- patients. *Trav Med Infect Dis* 2017. <https://doi.org/10.1016/j.tmaid.2017.10.004>.
- [26] Al-Tawfiq JA, Auwaerter PG. Healthcare-associated infections: the hallmark of the Middle East respiratory syndrome coronavirus (MERS-CoV) with review of the literature. *J Hosp Infect* 2018. <https://doi.org/10.1016/j.jhin.2018.05.021>.
- [27] Thomas HL, Zhao H, Green HK, Boddington NL, Carvalho CFA, Osman HK, et al. Enhanced MERS coronavirus surveillance of travelers from the Middle East to England. *Emerg Infect Dis* 2014;20:1562–4. <https://doi.org/10.3201/eid2009.140817>.
- [28] Sridhar S, Brouqui P, Parola P, Gautret P. Imported cases of Middle East respiratory syndrome: an update. *Trav Med Infect Dis* 2015;13:106–9. <https://doi.org/10.1016/j.tmaid.2014.11.006>.
- [29] Granados A, Goodall EC, Luinstra K, Smieja M, Mahony J. Comparison of asymptomatic and symptomatic rhinovirus infections in university students: incidence, species diversity, and viral load. *Diagn Microbiol Infect Dis* 2015;82:292–6. <https://doi.org/10.1016/j.diagmicrobio.2015.05.001>.
- [30] Furuya-Kanamori L, Cox M, Milinovich GJ, Magalhaes RJS, Mackay IM, Yakob L. Heterogeneous and dynamic prevalence of asymptomatic influenza virus infections. *Emerg Infect Dis* 2016;22:1052–6. <https://doi.org/10.3201/eid2206.151080>.
- [31] Wilder-Smith A, Telesman MD, Heng BH, Earnest A, Ling AE, Leo YS. Asymptomatic SARS coronavirus infection among healthcare workers, Singapore. *Emerg Infect Dis* 2005;11:1142–5. <https://doi.org/10.3201/eid1107.041165>.
- [32] Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. *Open Med* 2009;3:e123–30.
- [33] The WHO Mers-Cov Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. *PLoS Curr* 2013;5. <https://doi.org/10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8>. pii: ecurrents.outbreaks.0bf719e352e7478f8ad85fa30.
- [34] Park GE, Ko J-H, Peck KR, Lee JY, Lee JY, Cho SY, et al. Control of an outbreak of Middle East respiratory syndrome in a tertiary hospital in Korea. *Ann Intern Med* 2016;165:87. <https://doi.org/10.7326/M15-2495>.
- [35] Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. *Ann Intern Med* 2014;160:389–97. <https://doi.org/10.7326/M13-2486>.
- [36] Song Y, Yang J-S, Cheong H-K, Yoon HJ, Nam H-S, Lee SY, et al. Asymptomatic infection of Middle East respiratory syndrome coronavirus using serologic survey in Korea. *Epidemiol Health* 2018:e2018014. <https://doi.org/10.4178/epih.e2018014>.
- [37] Drosten C, Meyer B, Müller MAM, A, Corman VMVM, Al-Masri M, Hossain R, et al. Transmission of MERS-coronavirus in household contacts. *N Engl J Med* 2014;371:828–35. <https://doi.org/10.1056/NEJMoa1405858>.
- [38] Memish ZAZA, Al-Tawfiq JAJA, Assiri A, Alrabiah Fafa, Al Hajjar S, Albarrak A, et al. Middle East respiratory syndrome coronavirus disease in children. *Pediatr Infect Dis J* 2014;33:904–6. <https://doi.org/10.1097/INF.0000000000000325>.
- [39] Al-Tawfiq JA, Kattan RF, Memish ZA. Middle East respiratory syndrome coronavirus disease is rare in children: an update from Saudi Arabia. *World J Clin Pediatr* 2016;5:391–6. <https://doi.org/10.5409/wjcp.v5.i4.391>.
- [40] Alfaraj SH, Al-Tawfiq JA, Altuwajiri TA, Memish ZA. Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia. *Front Med* 2018. <https://doi.org/10.1007/s11684-017-0603-y>.
- [41] Amer H, Alqahtani AS, Alaklobi F, Altayeb J, Memish ZA. Healthcare worker exposure to Middle East respiratory syndrome coronavirus (MERS-CoV): revision of screening strategies urgently needed. *Int J Infect Dis* 2018;71:113–6. <https://doi.org/10.1016/j.ijid.2018.04.001>.
- [42] Haagmans BL, van den Brand JMA, Provacia LB, Raj VS, Stittelaar KJ, Getu S, et al. Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits. *J Virol* 2015;89:6131–5. <https://doi.org/10.1128/JVI.00661-15>.
- [43] Al Hammadi ZM, Chu DKW, Eltahir YM, Al Hosani F, Al Mulla M, Tarnini W, et al. Asymptomatic MERS-CoV infection in humans possibly linked to infected dro-mediaries imported from Oman to United Arab Emirates, May 2015. *Emerg Infect Dis* 2015;21:2197–200. <https://doi.org/10.3201/eid2112.151132>.
- [44] Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus: epidemiology and disease control measures. *Infect Drug Resist* 2014;7:281–7. <https://doi.org/10.2147/IDR.S51283>.
- [45] Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. *Lancet* (London, England) 2015;386:995–1007. [https://doi.org/10.1016/S0140-6736\(15\)60454-8](https://doi.org/10.1016/S0140-6736(15)60454-8).
- [46] Choe PG, Perera RAPM, Park WB, Song K-H, Bang JH, Kim ES, et al. MERS-CoV antibody responses 1 Year after symptom onset, South Korea, 2015. *Emerg Infect Dis* 2017;23:1079–84. <https://doi.org/10.3201/eid2307.170310>.
- [47] Thabet F, Chehab M, Bafaqih H, Al Mohaimed S. Middle East respiratory syndrome coronavirus in children. *Saudi Med J* 2015;36:484–6. <https://doi.org/10.15537/smj.2015.4.10243>.
- [48] World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) WHO MERS global summary and assessment of risk August 2018. http://www.who.int/csr/disease/coronavirus_infections/risk-assessment-august-2018.pdf?ua=1; 2018, Accessed date: 2 October 2018.
- [49] Al-Tawfiq JA, Zumla A, Memish ZA. Travel implications of emerging coronaviruses: SARS and MERS-CoV. *Trav Med Infect Dis* 2014;12:422–8. <https://doi.org/10.1016/j.tmaid.2014.06.007>.
- [50] Omrani AS, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA, Albarrak AM. A family cluster of middle east respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. *Int J Infect Dis* 2013;17:e668–72. <https://doi.org/10.1016/j.ijid.2013.07.001>.
- [51] Moon S, Son JS. Infectivity of an asymptomatic patient with Middle East respiratory syndrome coronavirus infection. *Clin Infect Dis* 2017;64:1457–8. <https://doi.org/10.1093/cid/cix170>.
- [52] Al Hosani FI, Kim L, Khudhair A, Pham H, Al Mulla M, Al Bandar Z, et al. Serologic follow-up of Middle East respiratory syndrome coronavirus cases and contacts - Abu Dhabi, United Arab Emirates. *Clin Infect Dis* 2018. <https://doi.org/10.1093/cid/ciy503>.
- [53] Alfaraj SH, Al-Tawfiq JA, Altuwajiri TA, Alanazi M, Alzahrani N, Memish ZA. Middle East respiratory syndrome coronavirus transmission among health care workers: implication for infection control. *Am J Infect Contr* 2018;46:165–8. <https://doi.org/10.1016/j.ajic.2017.08.010>.
- [54] Al-Abdely HM, Midgley CM, Alkhamis AM, Abedi GR, Tamin A, Binder AM, et al. Infectious MERS-CoV isolated from a mildly ill patient, Saudi Arabia. *Open Forum Infect Dis* 2018;5. <https://doi.org/10.1093/ofid/ofy111>.
- [55] Gardner LM, Chughtai AA, MacIntyre CR. Risk of global spread of Middle East respiratory syndrome coronavirus (MERS-CoV) via the air transport network. *J Trav Med* 2016;23:taw063. <https://doi.org/10.1093/jtm/taw063>.
- [56] Memish ZA, Almasri M, Turkestani A, Al-Shangiti AM, Yezli S. Etiology of severe community-acquired pneumonia during the 2013 Hajj-part of the MERS-CoV surveillance program. *Int J Infect Dis* 2014;25:186–90. <https://doi.org/10.1016/j.ijid.2014.06.003>.
- [57] Kandeel A, Deming M, Elkream EA, El-Refay S, Afifi S, Abukela M, et al. Pandemic (H1N1) 2009 and Hajj pilgrims who received predeparture vaccination, Egypt. *Emerg Infect Dis* 2011;17:1266–8. <https://doi.org/10.3201/eid1707.101484>.
- [58] Rashid H, Shafi S, Haworth E, El Bashir H, Memish ZA, Sudhanva M, et al. Viral respiratory infections at the Hajj: comparison between UK and Saudi pilgrims. *Clin Microbiol Infect* 2008;14:569–74. <https://doi.org/10.1111/j.1469-0691.2008.01987.x>.
- [59] Al-Tawfiq JA, Smallwood CAH, Arbutnot KG, Malik MSK, Barbeschi M, Memish ZA. Emerging respiratory and novel coronavirus 2012 infections and mass gatherings. *East Mediterr Health J* 2013;19(Suppl 1):S48–54.
- [60] Memish ZA, Zumla A, Al-Tawfiq JA. How great is the risk of Middle East respiratory syndrome coronavirus to the global population? *Expert Rev Anti Infect Ther* 2013;11:979–81. <https://doi.org/10.1586/14787210.2013.836965>.
- [61] Al-Tawfiq JA, Memish ZA. Mass gathering medicine: 2014 Hajj and Umra preparation as a leading example. *Int J Infect Dis* 2014;27:26–31.
- [62] Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. *Osong Public Heal Res Perspect* 2015;6:269–78. <https://doi.org/10.1016/j.phrp.2015.08.006>.
- [63] Pavli A, Tsiodras S, Maltzev HC. Middle East respiratory syndrome coronavirus (MERS-CoV): prevention in travelers. *Trav Med Infect Dis* 2014;12:602–8. <https://doi.org/10.1016/j.tmaid.2014.10.006>.
- [64] Gautret P, Charrel R, Benkouiten S, Belhouchat K, Nougairede A, Drali T, et al. Lack of MERS coronavirus but prevalence of influenza virus in French pilgrims after 2013 Hajj. *Emerg Infect Dis* 2014;20:728–30. <https://doi.org/10.3201/eid2004.131708>.
- [65] Aberle JH, Popow-Kraupp T, Kreidl P, Laferl H, Heinz FX, Aberle SW. Influenza A and B viruses but not MERS-CoV in Hajj pilgrims, Austria, 2014. *Emerg Infect Dis* 2015;21:726–7. <https://doi.org/10.3201/eid2104.141745>.
- [66] Gardner LM, Rey D, Heywood AE, Toms R, Wood J, Travis Waller S, et al. A scenario-based evaluation of the Middle East respiratory syndrome coronavirus and the Hajj. *Risk Anal* 2014;34:1391–400. <https://doi.org/10.1111/risa.12253>.
- [67] Lessler J, Rodriguez-Barraquer I, Cummings D a T, Garske T, Van Kerkhove M, Mills H, et al. Estimating potential incidence of MERS-CoV associated with Hajj pilgrims to Saudi Arabia, 2014. *PLoS Curr* 2014;6:1–18. <https://doi.org/10.1371/currents.outbreaks.c5c9c9abd636164a9b6fd4bdba974369>.
- [68] Gautret P, Charrel R, Belhouchat K, Drali T, Benkouiten S, Nougairede A, et al. Lack of nasal carriage of novel corona virus (HCoV-EMC) in French Hajj pilgrims returning from the Hajj 2012, despite a high rate of respiratory symptoms. *Clin Microbiol Infect* 2013;19:E315–7. <https://doi.org/10.1111/1469-0691.12174>.
- [69] Barasheed O, Rashid H, Alfelali M, Tashani M, Azeem M, Bokhary H, et al. Viral respiratory infections among Hajj pilgrims in 2013. *Virol Sin* 2014;29:364–71. <https://doi.org/10.1007/s12250-014-3507-x>.
- [70] Baharoon S, Al-Jahdali H, Al Hashmi J, Memish ZA, Ahmed QA. Severe sepsis and septic shock at the Hajj: etiologies and outcomes. *Trav Med Infect Dis* 2009;7:247–52. <https://doi.org/10.1016/j.tmaid.2008.09.002>.
- [71] Memish ZA, Assiri A, Almasri M, Alhakeem RF, Turkestani A, Al Rabeeh AA, et al. Prevalence of MERS-CoV nasal carriage and compliance with the Saudi health recommendations among pilgrims attending the 2013 Hajj. *J Infect Dis* 2014;210:1067–72. <https://doi.org/10.1093/infdis/jiu150>.
- [72] Annan A, Owusu M, Marfo KS, Larbi R, Sarpong FN, Adu-Sarkodie Y, et al. High prevalence of common respiratory viruses and no evidence of Middle East respiratory syndrome coronavirus in Hajj pilgrims returning to Ghana, 2013. *Trop Med Int Health* 2015;20:807–12. <https://doi.org/10.1111/tmi.12482>.
- [73] Refaey S, Amin MM, Roguski K, Azziz-Baumgartner E, Uyeki TM, Labib M, et al. Cross-Sectional survey and surveillance for influenza viruses and MERS-CoV among Egyptian pilgrims returning from Hajj during 2012–2015. *Influenza Other Respir Viruses* 2016. <https://doi.org/10.1111/irv.12429>.
- [74] Atabani SF, Wilson S, Overton-Lewis C, Workman J, Kidd IM, Petersen E, et al. Active screening and surveillance in the United Kingdom for Middle East respiratory syndrome coronavirus in returning travellers and pilgrims from the Middle East: a prospective descriptive study for the period 2013–2015. *Int J Infect Dis* 2016;47:10–4. <https://doi.org/10.1016/j.ijid.2016.04.016>.
- [75] ProMed. Novel coronavirus – Eastern Mediterranean (03): Saudi comment, 12 February 2013. <http://promedmail.org/post/20130326.1603038>; 2013.
- [76] Griffiths K, Charrel R, Lagier J-C, Nougairede A, Simon F, Parola P, et al. Infections in symptomatic travelers returning from the Arabian peninsula to France: a retrospective cross-sectional study. *Trav Med Infect Dis* 2016;14:414–6. <https://doi.org/10.1016/j.tmaid.2016.05.002>.

- [77] Memish ZA, Assiri A, Turkestani A, Yezli S, Al Masri M, Charrel R, et al. Mass gathering and globalization of respiratory pathogens during the 2013 Hajj. *Clin Microbiol Infect* 2015;21:571. <https://doi.org/10.1016/j.cmi.2015.02.008>. e1–8.
- [78] Benkouiten S, Charrel R, Belhouchat K, Drali T, Nougairede A, Salez N, et al. Respiratory viruses and bacteria among pilgrims during the 2013 Hajj. *Emerg Infect Dis* 2014;20:1821–7. <https://doi.org/10.3201/eid2011.140600>.
- [79] Ma X, Liu F, Liu L, Zhang L, Lu M, Abudukadeer A, et al. No MERS-CoV but positive influenza viruses in returning Hajj pilgrims, China, 2013–2015. *BMC Infect Dis* 2017;17:715. <https://doi.org/10.1186/s12879-017-2791-0>.
- [80] Al-Abdallat MM, Rha B, Alqasrawi S, Payne DC, Iblan I, Binder AM, et al. Acute respiratory infections among returning Hajj pilgrims—Jordan, 2014. *J Clin Virol* 2017;89:34–7. <https://doi.org/10.1016/j.jcv.2017.01.010>.
- [81] Koul PA, Mir H, Saha S, Chadha MS, Potdar V, Widdowson M-A, et al. Influenza not MERS CoV among returning Hajj and Umrah pilgrims with respiratory illness, Kashmir, North India, 2014–15. *Trav Med Infect Dis* 2017;15:45–7. <https://doi.org/10.1016/j.tmaid.2016.12.002>.
- [82] Kraaij-Dirkzwager M, Timen A, Dirksen K, Gelinck L, Leyten E, Groeneveld P, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in The Netherlands, May 2014. *Euro Surveill* 2014;19. pii: 20817.
- [83] Fanoy EB, van der Sande MA, Kraaij-Dirkzwager M, Dirksen K, Jonges M, van der Hoek W, et al. Travel-related MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch travellers returning from the Kingdom of Saudi Arabia, May 2014. *Emerg Themes Epidemiol* 2014;11:16. <https://doi.org/10.1186/1742-7622-11-16>.
- [84] ProMed. MERS-CoV - Eastern Mediterranean (73): Saudi Arabia, Algeria, Jordan. WHO, RFI; 2014 <http://www.promedmail.org/post/20140601.2512766>, Accessed date: 11 November 2016.
- [85] ProMed. MERS-CoV - Eastern Mediterranean (80): S Arabia, Iran, Algeria, Tunisia, n.d. <http://promedmail.chip.org/pipermail/promed/2014-June/004423.html>.
- [86] ProMed. MERS-CoV (01): Bangladesh, KSA, Algeria, UAE, Iran. WHO; 2014. RFI Archive Number: 20140616.2541707 <http://www.promedmail.org/post/20140616.2541707>.
- [87] World Health Organization. Management of asymptomatic persons who are RT-PCR positive for Middle East respiratory syndrome coronavirus (MERS-CoV) Interim guidance. http://apps.who.int/iris/bitstream/handle/10665/180973/WHO_MERS_IPC_15.2_eng.pdf;jsessionid=F362DEB01D8550505DDF4C962CD62479?sequence=1; 2018, Accessed date: 22 July 2018.
- [88] Memish ZA, Assiri AM, Al-Tawfiq JA. Middle East respiratory syndrome coronavirus (MERS-CoV) viral shedding in the respiratory tract: an observational analysis with infection control implications. *Int J Infect Dis* 2014;29:307–8. <https://doi.org/10.1016/j.ijid.2014.10.002>.
- [89] Al-Gethamy M, Corman VM, Hussain R, Al-Tawfiq JA, Drosten C, Memish ZA. A case of long-term excretion and subclinical infection with middle east respiratory syndrome coronavirus in a healthcare worker. *Clin Infect Dis* 2015;60. <https://doi.org/10.1093/cid/ciu1135>.